Kurin Challenges $1.6M IP Verdict Amid Rival’s Bid for Additional Damages
By Editorial Team
Kurin, a company entangled in a legal battle with Magnolia Medical, has taken steps to contest a $1.6 million patent verdict issued against them. In response, Magnolia Medical is seeking more damages from Kurin. The dispute revolves around alleged patent infringement related to Kurin’s “Jet” blood-culture collection products.
Kurin has petitioned a Delaware federal judge to either overturn the $1.6 million verdict in favor of Magnolia Medical or order a new trial. On the other hand, Magnolia Medical is urging the court to prevent Kurin from selling the disputed products, seek supplemental damages based on Kurin’s sales, demand ongoing royalties, and request interest on the damages.
The case involves several patents, including 11,529,081, 11,653,863, 11,903,709, and 12,138,052, which pertain to fluid control devices and methods of using them, as well as a blood sample optimization device.
The legal teams representing the parties include Davis Polk, Kirkland & Ellis, Morris Nichols, and Richards Layton. The litigation is before the U.S. District Court for the District of Delaware.
Both Kurin and Magnolia Medical are engaged in a fierce legal battle, with each side presenting arguments and motions to protect their interests. The outcome of this dispute will have significant implications for both companies in the intellectual property arena.
